-Former NYSE biotech.
-41 million OS.
-$3.5 million in cash on balance sheet.
-Trading at a market cap of $800,000.
-Company being shopped by management for a merger/buyout (confirmed by IR as of 12/14/18)- with NO debt, all proceeds go to shareholders :)
-Valuable cancer IP and a CLEAN shell for merger.
-October 15, 2018 PR: "ImmunoCellular may continue efforts to pursue opportunities for partnerships, licensing or sale of its anticancer assets and research programs, and monetization of the its dendritic cell-based and Stem-to-T-cell intellectual property . . . . . . ."
ImmunoCellular Therapeutics continues to make significant progress in meeting important goals and positioning the company for success. We believe that our cancer vaccine platform has the potential to be transformative in the treatment of cancer, and to create value for all our stakeholders. Our goal is to build ImmunoCellular into a leading, independent commercial-stage cancer immunotherapy company.
Our dendritic cell (DC) vaccine technology and advanced manufacturing offer several advantages over earlier-generation cellular immunotherapies:
- Matured DCs secrete IL12, which is critical for stimulating T cell killing of cancer cells.
More than 80% of the final manufactured product consists of matured DCs.
- Unlike other cell-based vaccines, our DCs target multiple antigens, thus increasing the likelihood of effective treatment.
- Advanced manufacturing enables production of at least 20 doses of vaccine from a single apheresis (blood collection); thus patients do not need to undergo additional apheresis procedures.
- Compared to the only approved cell-based immunotherapy, our DC vaccines can be manufactured at a significantly reduced cost.
- Ability to freeze and store vaccine for months or years eliminates the need to administer to the patient shortly after manufacture.
- Intradermal administration route reduces the time and inconvenience of intravenous infusion for both patient and physician.
21900 Burbank, 3rd Floor
Woodland Hills, CA 91367
Press Releases: http://imuc.com/press/
U.S. Stock Transfer Corp.
Glendale, CA 91204-2991
Gary Nash, CEOcast, Inc.
ImmunoCellular has concluded a phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. ImmunoCellular's pipeline also includes: ICT-121, a dendritic cell vaccine targeting CD133; ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells; and the Stem-to-T-cell research program which engineers the patient's hematopoietic stem cells to generate antigen-specific cancer killing T-cells.
Announced the establishment of an agreement with PharmaCell B.V. to provide contract manufacturing services for the European production of ICT-107, a dendritic cell-based cancer immunotherapy in development as a potential treatment for glioblastoma (GBM). This agreement with PharmaCell, a leading European contract manufacturing organization focuses on the production of human cell therapy products, and is designed to enable ImmunoCellular to access phase 3 supplies of ICT-107, manufactured with ImmunoCellular's commercial-ready production process. ImmunoCellular intends to initiate a Phase 3 registrational program for ICT-107 in the US and in Europe in 2015.
>>> What these CANCER vaccines could be worth
Investor Presentation -> http://files.shareholder.com/downloads/AMDA-1HS8HT/61684022x0x652321/5FD13B20-8F93-44CE-994E-D5515E5F30FC/IMI_Corporate_Overview.pdf